Effects of pentoxifylline on liver regeneration: A double-blinded, randomized, controlled trial in 101 patients undergoing major liver resection

Annals of Surgery

Volumn 252, Issue 5, 2010, Pages 813-821

  Petrowsky, Henrik ^a   Breitenstein, Stefan ^a   Slankamenac, Ksenija ^a   Vetter, Diana ^a   Lehmann, Kuno ^a   Heinrich, Stefan ^a   Deoliveira, Michelle L ^a   Jochum, Wolfram ^b   Weishaupt, Dominik ^b   Frauenfelder, Thomas ^c   Graf, Rolf ^a   Clavien, Pierre Alain ^a  

^a Swiss HPB (Hepato Pancreato Biliary) Center   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; CYTOKINE; INTERLEUKIN 6; MESSENGER RNA; PENTOXIFYLLINE; PLACEBO; ANTINEOPLASTIC AGENT; RINGER LACTATE SOLUTION;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART ARREST; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LIVER ISCHEMIA; LIVER REGENERATION; LIVER RESECTION; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TOMOGRAPHY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BLOATING; BODY WEIGHT; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; DEMOGRAPHY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL MOTILITY DISORDER; HEART ARRHYTHMIA; HEARTBURN; HOT FLUSH; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER INJURY; LIVER METASTASIS; LIVER SURGERY; LIVER TRANSPLANTATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPERATION DURATION; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; REMNANT LIVER TO BODY WEIGHT RATIO; REPERFUSION INJURY; RISK FACTOR; SURGICAL PATIENT; TACHYCARDIA; TERTIARY HEALTH CARE; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; VOLUMETRY; VOMITING;

BIOPSY; DOUBLE-BLIND METHOD; FEMALE; HEPATECTOMY; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER REGENERATION; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955684027     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181fcbc5e     Document Type: Conference Paper

References (30)

1. Clavien PA, Oberkofler C, Raptis D, et al. What is critical for liver surgery and partial livertransplantation\size or quality? Hepatology. 2010;52:715-729.
2. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgeryandpartiallivertransplantation. N Engl J Med. 2007;356:1545-1559.
3. Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms ofdisease, and clinical implications. Am J Transplant. 2005;5:2605-2610.
4. Tanaka K, Yamada T. Living donor liver transplantation in Japan and Kyoto University: what can we learn?J Hepatol. 2005;42:25-28.
5. Breitenstein S, Apestegui C, Petrowsky H, et al. "State of the art" in liver resection and living donor liver transplantation: a worldwide survey of 100 livercenters. World J Surg. 2009;33:797-803.
6. Tian Y, Jochum W, Georgiev P, et al. Kupffer cell-dependent TNF-alpha signaling mediates injury in the arterialized small-for-size liver transplantation in the mouse. Proc Natl Acad Sci USA. 2006;103: 4598-4603.
7. 31P NMR and ultrastructural studies. NMR Biomed. 1991;4:286-293.
8. Bachmann S, Caldwell-Kenkel JC, Currin RT, et al. Ultrastructural correlates ofliver graft failure from storage injury: studies of graft protection by Carolina rinsesolutionandpentoxifylline. Transplant Proc. 1993;25:1620-1624.
9. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637-1648.
10. Bath PM, Bath-Hextall FJ. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev. 2004:CD000162.
11. Jull A, Waters J, Arroll B. Pentoxifylline for treatment of venous leg ulcers: a systematic review. Lancet. 2002;359:1550-1554.
12. Lesurtel M, Selzner M, Petrowsky H, et al. How should transection of the liver be performed? A prospective randomized study in 100 consecutive patients: comparing four differenttransectionstrategies.Ann Surg. 2005;242:814-822, 22-23; discussion.
13. Clavien PA, Yadav S, Sindram D, et al. Protective effects ofischemic precon-ditioning for liver resection performed under inflow occlusion in humans. Ann Surg. 2000;232:155-162.
14. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of6336 patients and results of a survey. Ann Surg. 2004;240:205-13.
15. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-186.
16. Aslanyan S, Weir CJ, Muir KW, et al. Magnesium for treatment ofacute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke. 2007;38:1269-1273.
17. Reilly HM, Martineau JK, Moran A, et al. Nutritional screening-evaluation and implementation of a simple nutrition risk score. Clin Nutr. 1995;14:269-273.
18. http://www.medsafe.govt.nz/Profs/Datasheet/t/Trentaltabinj.htm. Accessed January 2010.
19. http://www.sanofi-aventis.ca/products/en/trental.pdf Accessed Januray 2010.
20. Kucuktulu U, Alhan E, Tekelioglu Y, et al. The effects ofpentoxifylline on liver regeneration after portal vein ligation in rats. Liver Int. 2007;27:274-279.
21. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274:1379-1383.
22. Yamada Y, Kirillova I, Peschon JJ, et al. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necro-sis factorreceptor. Proc Natl Acad Sci US A. 1997;94:1441-1446.
23. Jin X, Zhang Z, Beer-Stolz D, et al. Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology. 2007;46:802-812.
24. El-Ghoneimi A, Cursio R, Schmid-Alliana A, et al. Pentoxifylline inhibits liver expression of tumor necrosis factor alpha mRNA following normothermic ischemia-reperfusion.HPB (Oxford). 2007;9:112-119.
25. Peng XX, Currin RT, Thurman RG, et al. Protection by pentoxifylline against normothermic liver ischemia/reperfusion in rats. Transplantation. 1995;59:1537-1541.
26. Fabia R, Travis D L, Levy MF, et al. Effect ofpentoxifylline onhepatic ischemia and reperfusi on injury Surgery. 1997;121:520-525.
27. Abu-Amara M, Gurusamy KS, Glantzounis G, et al. Pharmacological inter-ventions for ischaemia reperfusion injury in liver resection surgery performed undervascularcontrol. Cochrane Database Syst Rev. 2009:CD008154.
28. Stadheim LM, Gores GJ, Lee TC, et al. Normothermic ischemia-reperfusion injury during hepatic resection: a prospective randomized placebo con-trolled study ofpretreatment with misoprostol or pentoxifylline. Hepatology 2000;32:250A.
29. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatec-tomies in the 1990s: an update to evaluate the actual risk ofliver resection. J Am Coll Surg. 2000;191:38-46.
30. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of1,803 consecutive cases over the past decade. Ann Surg. 2002;236:397-406; discussion407.